TriangleCediranib (NCT04090567)
Cediranib trial for Advanced Breast Carcinoma (NCT04090567). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for women older than 18 with advanced HER2-negative breast cancer and an inherited BRCA mutation, progressing after at least two months of PARP-inhibitor treatment. ER-positive disease requires prior endocrine progression or unsuitable endocrine options.
The idea: combine DNA-repair inhibitor olaparib with either cediranib, which blocks blood-vessel growth signals, or ceralasertib, which disrupts DNA-damage responses. Random assignment selects the oral combination. Fresh tumor biopsy is required; researchers measure tumor responses.
This phase 2 study plans 60 patients. Banu Arun leads it at MD Anderson in Houston, the single recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.